Form 4: BIODESIX CFO Cowie Reports RSU Vesting, Tax-Related Stock Sale

BIODESIX CFO Robin Harper Cowie reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Robin Harper Cowie, CFO, Secretary, and Treasurer of BIODESIX INC, reported transactions involving the company's common stock and restricted stock units (RSUs).
• On February 20, 2026, 1,469 shares of common stock were acquired upon the vesting of RSUs.
• Following this acquisition, Cowie beneficially owned 16,766 shares of common stock directly.
• On February 23, 2026, 535 shares of common stock were sold at a weighted average price of $12.7756 per share.
• This sale was an automatic transaction to cover tax obligations related to the RSU vesting.
• The shares sold for tax purposes ranged in price from $12.58 to $13.16.
• After the sale, Cowie directly beneficially owned 16,231 shares of common stock.
• The RSU numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.
• Remaining 4,406 RSUs are beneficially owned, vesting in four equal annual installments from February 20, 2025, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical of executive compensation and tax management. It reflects routine RSU vesting and a standard tax-related stock sale, with no significant positive or negative implications for the company's operational or financial performance.

Positives

• Vesting of 1,469 Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.
• The executive's continued service with the Issuer is implied by the vesting schedule.

Negatives

• A sale of 535 shares of common stock, even for tax purposes, reduces the executive's direct ownership in the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the remaining Restricted Stock Units, which are contingent on the reporting person's continued service.

Management Comments

• The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common across industries. These transactions primarily reflect executive compensation structures and do not typically indicate a shift in broader industry trends or competitive landscape.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of granting Restricted Stock Units (RSUs) as a form of executive compensation, with vesting contingent on continued service, is a standard practice across many publicly traded companies, particularly in the biotechnology and diagnostics sectors where BIODESIX operates.
• The automatic sale of shares to cover tax obligations upon vesting is also a common and expected mechanism for managing equity compensation, aligning with practices seen at companies like Guardant Health (GH) or Exact Sciences (EXAS) which also utilize equity-based incentives for their executives.

Related Party Transactions

• The vesting and acquisition of common stock from Restricted Stock Units (RSUs) is a form of compensation from the issuer to a key executive, constituting a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even for tax purposes, slightly reduces the executive's direct ownership, but the overall impact on shareholder value from this routine transaction is minimal.
• Employees: The RSU vesting demonstrates the company's commitment to executive compensation and retention, which can positively influence employee morale and retention strategies.

Next Steps

• The remaining 4,406 Restricted Stock Units (RSUs) will continue to vest in successive equal annual installments from February 20, 2025, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are standard components of executive compensation and do not typically signal a change in the company's fundamental outlook or operational performance. Therefore, based solely on this filing, a seasoned investor would likely maintain their current position, as there is no new information to warrant a 'buy' or 'sell' recommendation.

Keywords

BIODESIX, BDSX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, CFO, Robin Harper Cowie, Executive Compensation, Reverse Stock Split